LI-COR IRDye® 800CW PEG 荧光造影剂,LI-COR IRDye® 800CW PEG

Reagents > IRDye® 800CW PEG Fluorescent Contrast Agent,IRDye® 800CW PEG 荧光造影剂

IRDye® 800CW PEG Fluorescent Contrast Agent

IRDye 800CW PEG Contrast Agent (25-60 kDa) is a non-specific imaging agent intended to exploit enhanced permeability and retention (EPR) in tumor biology.

EPR is a common characteristic of tumor vasculature. The vascular endothelium in the tumor microenvironment is often discontinuous, allowing molecules to diffuse into the surrounding tumor tissue.1, 2 In addition to EPR, the lymphatic drainage for these regions is poor.3 Hence, larger molecules tend to accumulate.

IRDye 800CW PEG 造影剂 (25-60 kDa) 是一种非特异性显像剂，旨在利用肿瘤生物学中的增强渗透性和保留 (EPR)。

EPR是肿瘤脉管系统的共同特征。 肿瘤微环境中的血管内皮通常是不连续的，允许分子扩散到周围的肿瘤组织中。1, 2 除了 EPR，这些区域的淋巴引流很差。3 因此，较大的分子往往会积聚。

Learn more about LI-COR optical probes.

Applications

  • Vascular/Lymphatic Imaging
  • Molecular Activity Measurements

Absorbance and Emission Spectra

IRDye® 800CW PEG Fluorescent Contrast Agent

Data Examples

In appropriate mouse models, the agent highlights surface vasculature for approximately 0.5 hour post-injection as seen in Figure 1. Approximately 4 hours post-injection, retention of the labeled macromolecule is visible in the tumor (Figure 2). At 9 hours post-intravenous injection the tumor is well defined (Figure 3).

IRDye 800CW PEG Contrast Agent may also be used effectively as a lymph tracking agent when given intradermally (Figure 4). Images captured on the Pearl® Imaging System.

IRDye® 800CW PEG Fluorescent Contrast Agent
Figure 1. Athymic male nu/nu mouse (~5-6 wks old) 0.5 hour after receiving IRDye 800CW PEG (1 nmol) intravenously. Surface blood vessels are visible. Vascular feature is mouse model dependent, see pack insert for Precautions.
IRDye® 800CW PEG Fluorescent Contrast Agent
Figure 2. Athymic male nu/nu mouse approximately 4 hours after receiving IRDye 800CW PEG (1 nmol) intravenously.Large blood vessels and tumor are visible.
IRDye® 800CW PEG Fluorescent Contrast Agent
Figure 3. Athymic male nu/nu mouse approximately 9 hours after receiving IRDye 800CW PEG (1 nmol) intravenously. Tumor is clearly defined.
IRDye® 800CW PEG Fluorescent Contrast Agent
Figure 4. Athymic male nu/nu mouse minutes after receiving IRDye 800CW PEG (~0.1 nmole) intradermally on the tail (right side). Image highlights use of IRDye PEG as a lymph imaging agent.

References

  1. Vasey, P.A., et al. (1999) Clin, Cancer Res, 5:83-94.
  2. Matsumura, Y. and H. Maeda. (1986) Cancer Res, 46:6387-6392.
  3. Seymour, L.W. (1992) Crit. Rev. Ther. Drug Carrier Syst, 9(2):135-187.

发表评论